Post Profile






Custirsen shows no survival benefits in metastatic prostate cancer

(European Society for Medical Oncology) A phase III randomized controlled trial of custirsen in combination with cabazitaxel/prednisone in patients with previously-treated metastatic, castration-resistant prostate cancer has shown no significant survival gains compared to cabazitaxel/prednisone alone, according to data presented at the ESMO 2016 Congress in Copenhagen
read more

share

Related Posts


Improved Survival In Patients With Bone Metastases And Advanced Prostate Cancer In First Phase III Trial Of An Alpha-Pharmaceutical

Health : Medical News Today

Until recently, options for patients with bone metastases from advanced prostate cancer have been very limited. But now the first Phase III study of an alpha-pharmaceutical in these patients has shown that it can prolong survival si...

JEVTANA(R) (Cabazitaxel) Is Now Available In The UK For The Treatment Of Men With Advanced Prostate Cancer Resistant To Other Therapy

Health : Medical News Today

Sanofi-aventis announced today that it has launched JEVTANA in combination with prednisone/prednisolone for the treatment of men with mHRPC previously treated with docetaxel. Men with this stage of cancer typically have a poor progn...

Immunotherapy: Promising results in first & second line treatment of metastatic bladder cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO 2016 Congress in Copenhagen.

Abiraterone Acetate Significantly Improves Overall Survival Of Patients With Post-Chemotherapy Metastatic Castration-Resistant Prostate Cancer

Health : Medical News Today

A study published today in The New England Journal of Medicine in patients with metastatic advanced prostate cancer following chemotherapy who were treated with abiraterone acetate plus prednisone/prednisolone showed a significant i...

Clinical Responses Demonstrated In Metastatic Castrate Resistant Prostate Cancer Patients Treated With BPX-101 Cancer Vaccine

Health : Medical News Today

Bellicum Pharmaceuticals, Inc. announced the presentation of Phase I/II safety and efficacy data for BPX-101, a novel drug-activated dendritic cell vaccine for metastatic castrate resistant prostate cancer (mCRPC), in three separate...

Comments


Copyright © 2016 Regator, LLC